Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 17/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 16/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dasb SCHEMBL586446 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3TDP1 | |
| Dasb SCHEMBL29459573 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3TDP1 | |
| Dasb SCHEMBL29689760 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3TDP1 | |
| SCHEMBL32890246 | 0.83 | SLC6A4 (0.70) | SLC6A4SLC6A2SLC6A3TDP1 | |
| SCHEMBL1645160 | 0.81 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3TDP1 | |
| SCHEMBL29993160 | 0.81 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3TDP1 | |
| SCHEMBL30543447 | 0.81 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3TDP1 | |
| SCHEMBL1644204 | 0.81 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3TDP1 | |
| SCHEMBL8533846 | 0.80 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3TDP1 | |
| SCHEMBL12728082 | 0.80 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12514937-B2 | Methods for detecting CCR2 receptors | WASHINGTON UNIVERSITY (US) | 2026-01-06 | — | — | US | claimed |
| US-20240009332-A1 | COMPOSITE EMBOLIZATION BEADS | TRANSLATIONAL AND FUNDAMENTAL TECHNOLOGIES INSTITUTE LLC | 2024-01-11 | — | — | US | claimed |
| US-11712487-B2 | Composite embolization beads | RAIKA MEDICAL IMAGING INC. (US) | 2023-08-01 | — | — | US | claimed |
| US-12544463-B2 | Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application | FIVE ELEVEN PHARMA INC. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4663637-A2 | NOVEL DEUTERIUM SUBSTITUTED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS AND THEIR PHARMACOLOGICAL APPLICATION | Five Eleven Pharma Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-3630757-B1 | NOVEL DEUTERIUM SUBSTITUTED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS AND THEIR PHARMACOLOGICAL APPLICATION | FIVE ELEVEN PHARMA INC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250082796-A1 | LABELED PROBE AND METHODS OF USE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-03-13 | — | — | US | disclosed |
| US-12186411-B2 | Labeled probe and methods of use | THE BOARD OF TRUSTEES OF LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240409514-A1 | METHODS FOR INHIBITING NATIVE AND PROMISCUOUS UPTAKE OF MONOAMINE NEUROTRANSMITTERS | ETHISMOS RESEARCH, INC. (US) | 2024-12-12 | — | — | US | disclosed |
| EP-4395772-A1 | METHODS OF PREVENTING AND TREATING PAIN AND ASSOCIATED SYMPTOMS | Ethismos Research, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-114539243-B | Novel deuterium-substituted Positron Emission Tomography (PET) imaging agent and pharmacological application thereof | 五一一制药股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| US-11518796-B2 | Engineered platelets for targeted delivery of a therapeutic agent | JPV01 LTD. (GB) | 2022-12-06 | — | — | US | disclosed |
| CN-110678465-B | Novel deuterium-substituted Positron Emission Tomography (PET) imaging agents and their pharmacological use | 五一一制药股份有限公司 | 2022-12-02 | — | — | CN | disclosed |
| US-20220251165-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-08-11 | — | — | US | disclosed |
| CN-114787355-A | Peptide-nucleic acid complex having blood-brain barrier penetrating ability and composition comprising the same | 海阳制药 | 2022-07-22 | — | — | CN | disclosed |
| EP-4026898-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-07-13 | — | — | EP | disclosed |
| CN-114539243-A | Novel deuterium-substituted Positron Emission Tomography (PET) imaging agents and their pharmacological use | 五一一制药股份有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20220062449-A1 | Labeled Probe and Methods of Use | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-03-03 | — | — | US | disclosed |
| US-20220040335-A1 | RADIOLABELED PABA AND DERIVATIVES THEREOF FOR USE AS FUNCTIONAL RENAL IMAGING AGENTS | THE JOHNS HOPKINS UNIVERSITY | 2022-02-10 | — | — | US | disclosed |
| US-20220041684-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12544463-B2 | Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application | SLC18A2, SLC6A3, SLCO1B3 | SLC6A4 4/4885SLC6A2 6/4885SLC6A3 2/4885 |
| US-20240409514-A1 | METHODS FOR INHIBITING NATIVE AND PROMISCUOUS UPTAKE OF MONOAMINE NEUROTRANSMITTERS | SLC18A2, SLC6A2, SLC18A3 | SLC6A4 5/4885SLC6A2 2/4885SLC6A3 4/4885 |
| US-20220040335-A1 | RADIOLABELED PABA AND DERIVATIVES THEREOF FOR USE AS FUNCTIONAL RENAL IMAGING AGENTS | PABPC1, HNRNPAB, HNRNPA1 | SLC6A4 3948/4885SLC6A2 3600/4885SLC6A3 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.